Skip to main content

Table 3 Mean (± SD) baseline and changes at endpoint in PANSS total, positive, negative, and anxiety/depression scores in the three groups of patients.

From: Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

PANSS

Abrupt (n= 29)

Gradual 1 (n= 34)

Gradual 2 (n= 31)

All Groups (n= 94)

Between-treatment p-valuea

Total

     

   Baseline

74.6 (± 10.6)

76.0 (± 12.3)

76.2 (± 11.6)

75.6 (± 11.5)

 

   Change

-7.5 (± 14.4)†

-4.9 (± 17.1)

-9.8 (± 15.1)‡

-7.3 (± 15.6)‡

0.1497

Positive

     

   Baseline

21.7 (± 4.2)

23.1 (± 5.2)

21.1 (± 5.5)

22.0 (± 5.1)

 

   Change

-3.4 (± 4.6)‡

-2.6 (± 6.4)*

-3.0 (± 4.9)†

-3.0 (± 5.4)‡

0.2009

Negative

     

   Baseline

17.9 (± 4.8)

18.1 (± 5.2)

19.5 (± 5.7)

18.5 (± 5.2)

 

   Change

-0.7 (± 6.0)

0.2 (± 6.2)

-2.2 (± 5.8)*

-0.9 (± 6.1)

0.2904

Anxiety/depression

     

   Baseline

11.1 (± 3.4)

10.3 (± 3.6)

10.9 (± 3.4)

10.7 (± 3.5)

 

   Change

-1.6 (± 3.6)*

-0.5 (± 3.6)

-2.2 (± 3.9)†

-1.4 (± 3.7)‡

0.618

  1. aFrom an analysis of covariance (ANCOVA) model with treatment, site, and baseline value as factors.
  2. *p < 0.05, †p < 0.01, ‡p < 0.001 versus baseline (paired t-test).